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The Value of Myocardial
Perfusion Single-Photon Emission Computed
Tomography in Screening Asymptomatic Patients
With Atrial Fibrillation for Coronary Artery Disease
J. Wells Askew, MD,* Todd D. Miller, MD, FACC,* David O. Hodge, MS,†
Raymond J. Gibbons, MD, FACC*
Rochester, Minnesota
Objectives We sought to determine if screening for coronary artery disease (CAD) with stress single-photon emission computed tomog-
raphy (SPECT) is of value in patients with atrial fibrillation (AF) who do not have symptoms of chest pain or dyspnea.
Background Although noninvasive stress testing is often done to screen for CAD in asymptomatic patients with AF and is con-
sidered to be appropriate in selected patients, its potential utility has not been demonstrated.
Methods A retrospective study was conducted of 374 asymptomatic patients with AF referred for the detection of CAD.
Mean follow-up was 5.7  3.8 years. The study group was compared with a control group of 374 asymptomatic
age and gender-matched patients without AF.
Results The mean summed stress score (SSS) was not significantly different between AF patients and control subjects
(3.6  5.3 vs. 3.5  5.9; p  0.35). Compared with controls, asymptomatic AF patients had similar rates of ab-
normal SPECT studies (51.6% vs. 48.4%; p  0.38) and high-risk studies (14.4% vs. 14.4%; p  1.0). The SSS
was a significant predictor of outcome in both AF patients and control subjects. However, total mortality was
significantly greater in AF patients (5-year overall mortality 27% vs. 18%, 10-year overall mortality 47% vs. 40%;
p  0.001), and this difference persisted (p  0.01) after adjusting for multiple clinical variables and the SSS.
Conclusions Screening for CAD using stress SPECT in asymptomatic AF patients has a yield similar to age- and gender-
matched control patients without AF. Although SSS predicts mortality in patients with and without AF, patients
with AF have increased total mortality independent of the findings on stress SPECT. These results suggest that
factors other than obstructive CAD are responsible for the increased mortality in AF. (J Am Coll Cardiol 2007;
50:1080–5) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.05.035o
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vtrial fibrillation (AF) is an independent predictor of mortality
1); however, the relationship between ischemic heart disease
nd AF has been variable. Atrial fibrillation patients (most
ith symptoms), have been reported to have more abnormal
yocardial perfusion single-photon emission computed tomo-
raphic (SPECT) studies and a higher risk of cardiac death
ompared with patients without AF (2).
rom the *Division of Cardiovascular Diseases, Department of Internal Medicine,
nd the †Division of Biostatistics, Department of Health Sciences Research, Mayo
linic and Mayo Clinic College of Medicine, Rochester, Minnesota. Dr. Miller has
eceived research grants from Radiant Medical, Boston Scientific, Bristol-Myers Squibb,
oehringer Ingelheim, Spectranetics, KAI Pharmaceuticals, TargeGen, and King Phar-
aceuticals. Dr. Gibbons has received research grants from Radiant Medical, Boston
cientific, Boehringer Ingelheim, Spectranetics, KAI Pharmaceuticals, TargeGen,
herOx, and King Pharmaceuticals and is a consultant for Hawaii Biotech, Cardiovas-
ular Clinical Studies (the WOMEN study), Consumers Union, and TIMI 37A.c
Manuscript received March 15, 2007; revised manuscript received April 30, 2007,
ccepted May 14, 2007.Given these reported associations between AF and cor-
nary artery disease (CAD), there is increased interest in
creening selected patients with AF for CAD, in an effort to
mprove their prognosis. Recent appropriateness criteria for
yocardial perfusion SPECT have been published (3).
hese criteria reported that it was appropriate to screen
symptomatic patients with new-onset AF who were at
igh clinical risk for CAD; in contrast, in patients at low
linical risk, screening was judged to be of uncertain
ppropriateness. Although AF may be associated with
AD, current practice guidelines (4) do not recommend
outine stress imaging and only recommend exercise testing
efore treatment of selected patients with a type IC antiar-
hythmic drug. The aim of the present study was to
etermine if screening for CAD with stress SPECT is of
alue in patients with AF who do not have symptoms of
hest pain or dyspnea or a history of CAD.
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atient population. The study was approved by the Mayo
linic Institutional Review Board. Patients referred for
tress SPECT between January 1986 and December 2003
ere identified using the nuclear cardiology database. Ex-
lusion criteria included: chest pain, dyspnea, history of
AD, valvular heart disease, left bundle branch block, and
aced rhythm. Patients with AF by electrocardiogram at the
ime of the stress study were then identified. The final study
opulation consisted of 374 asymptomatic patients (i.e., no
hest pain or dyspnea) referred for stress SPECT for the
urpose of CAD screening. Using identical exclusion crite-
ia, 374 age- and gender-matched controls without AF
eferred for stress SPECT for the purpose of CAD screen-
ng during that same time period were identified for
omparison purposes. As previously described (5), clinical
haracteristics were recorded prospectively.
linical risk score. A simple 10-point score was used to
stimate clinical risk. The clinical score is determined by
ssessing 5 variables (age, gender, prior myocardial infarc-
ion [MI], angina, and diabetes) each of which has an
ndependent association with angiographically determined
evere CAD (6). For the purpose of this study, only 3 of the
variables contributed to the overall score, because patients
ith angina or a history of MI were excluded. Patients were
ubdivided into groups of low clinical risk (score 4),
ntermediate clinical risk (score  5), and high clinical risk
score 6). These groupings have been shown to effectively
tratify levels of risk for overall mortality, cardiac death, and
ardiac death/MI (7).
tress testing, radionuclide imaging protocol, and image
nterpretation. These methods have been described previ-
usly (5). Patients referred for exercise (n  193 [51.6% of
he AF group] and n  195 [52.1% of the non-AF group])
nderwent a symptom-limited treadmill test (Bruce, mod-
fied Bruce, or Naughton protocol). Adenosine was the
harmacologic stress agent in 151 (40.4%) of the 374 AF
atients and 126 (33.7%) of the 374 non-AF patients, with
ess frequent use of dipyridamole (6.4% and 9.4%, respec-
ively) and dobutamine (1.6% and 4.8%, respectively). Pa-
ients receiving 201Tl (n  128 [34.2% of the AF patients]
nd n  165 [44.1% of the non-AF patients]) underwent a
-day protocol. Patients receiving 99mTc sestamibi (n 246
65.8% of the AF patients] and n  209 [55.9% of the
on-AF patients]) underwent either a 1-day or 2-day
rotocol. The summed rest score (SRS), summed stress
core (SSS), and summed difference score (SDS) were
etermined. Using previously published criteria, SSS results
ere divided into 3 groups: 0 to 3 (low risk), 4 to 8
intermediate risk), and9 (high risk) (8). Cardiac enlarge-
ent was determined by a qualitative visual assessment.
urvival analysis. Total mortality was determined using
he Social Security Death Index and Mayo Clinic records.
urvival was estimated using the Kaplan-Meier method.
ean duration of follow-up was 5.7  3.8 years.
Dtatistical analysis. Categoric
actors were compared between
roups using the chi-square test
or independence. The Wilcoxon
ank sum test was used to com-
are continuous variables. Poten-
ial risk factors for mortality were
valuated using Cox proportional
azards models. Differences be-
ween survival curves were com-
ared between groups using the
og rank test.
esults
aseline characteristics. The
linical characteristics of each group are shown in Table 1.
hereas patients with AF were more likely to be on
ate-controlling agents (beta-blockers and calcium-channel
lockers), only about a third of AF patients were taking
hese medications. A small number of AF patients (7.8%)
ere on antiarrhythmic medications. The clinical risk scores
id not differ between AF and non-AF patients.
tress test results. The stress test characteristics and re-
ults are shown in Table 2. Overall, the results of SPECT
maging were very similar between patients with and with-
ut AF. Approximately half of the patients in the AF and
on-AF groups had normal images (48.4% vs. 51.6%,
linical Characteristics and Baseline Medications
Table 1 Clinical Characteristics and Baseline Medications
AF Group
(n  374)
Non-AF Group
(n  374) p Value
Age, yrs (mean  SD) 69.1 9.5 69.1 9.5
Gender
Male 320 (85.6) 320 (85.6) 1.0
Female 54 (14.4) 54 (14.4)
Risk factors
Cigarette smoking 0.03
None 164 (44) 146 (39)
Current 30 (8.0) 52 (13.9)
Prior history 180 (48.1) 176 (47.0)
Diabetes 0.83
None 289 (77) 295 (79)
On insulin 26 (6.9) 26 (6.9)
Not on insulin 59 (15.8) 53 (14.2)
Hypertension 236 (63.1) 209 (55.9) 0.04
Hyperlipidemia 151 (40.4) 191 (51.1) 0.003
Family history of CAD 80 (21.4) 75 (20.1) 0.65
Medications
Beta-blockers 138 (36.9) 74 (19.8) 0.001
Calcium-channel blockers 125 (33.4) 68 (18.2) 0.001
Digoxin 194 (51.9) 17 (4.6) 0.001
Clinical risk score 0.99
Low 172 (46.0) 171 (45.7)
Intermediate 129 (34.5) 129 (34.5)
High 73 (19.5) 74 (19.8)
Abbreviations
and Acronyms
AF  atrial fibrillation
CAD  coronary artery
disease
MI  myocardial infarction
SDS  summed difference
score
SPECT  single-photon
emission computed
tomography
SRS  summed rest score
SSS  summed stress
scoreata are reported as n (%) unless otherwise indicated.
AF  atrial fibrillation; CAD  coronary artery disease.
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CAD Screening for Asymptomatic AF September 11, 2007:1080–5espectively; p  0.38). There were no significant differ-
nces between the AF and non-AF groups in the mean SSS,
he mean SDS, or the percentages of patients in the SSS
ategories (Fig. 1). The SRS in both AF and non-AF
roups was low; however, the area of fixed perfusion
bnormality was higher in the AF group. This may reflect
rior “silent MI” or fibrosis related to nonischemic cardio-
yopathy. Cardiac enlargement was more common in
atients with AF.
ssociation between clinical risk score and SSS. There
as no correlation between the clinical risk score and SSS in
atients with AF (p  0.97). There was a statistically
ignificant but weak correlation between the clinical risk
core and SSS in patients without AF (r 0.17; p 0.001).
he test for formal interaction between AF, the clinical risk
core, and SSS was significant (p  0.01), implying that the
elationship between the clinical risk score and SSS is
ifferent depending on the presence or absence of AF. In
tress Test Characteristics ofhe Study and Control Populations
Table 2 Stress Test Characteristics ofthe Study and Control Populations
AF Group Non-AF Group p Value
Resting heart rate, beats/min
(mean  SD)
81 18 72 13 0.001
Exercise stress 193 (51.6) 195 (52.1) 0.88
Duration, min (mean  SD) 7.0 2.1 8.7 4.5 0.001
Peak heart rate, beats/min
(mean  SD)
157 26 143 21 0.001
Ischemic ECG 20 (10.4) 59 (30.3) 0.001
Pharmacologic stress 181 (48.4) 179 (47.9) 0.88
Ischemic ECG 1 (0.6) 6 (3.4) 0.05
Summed perfusion scores
Summed rest score
(mean  SD)
1.7 3.4 1.4 3.4 0.03
Summed stress score
(mean  SD)
3.6 5.3 3.5 5.9 0.35
Summed difference score
(mean  SD)
1.9 3.1 2.1 3.7 0.63
Cardiac enlargement* 83 (22.2) 37 (9.9) 0.001
ata are reported as n (%) unless otherwise indicated. *Qualitative visual assessment.
AF  atrial fibrillation; ECG  electrocardiogram.
Figure 1 Summed Stress Score Results
in Patients With and Without Atrial Fibrillation
Solid bars  atrial fibrillation patients; open bars  non-atrial fibrillation
patients. *The p value for mean SSS between patients with and without atrial
fibrillation (p  0.35). SSS  summed stress score.iF patients, the clinical risk score was not helpful for
redicting a high-risk SSS, because 14.5% of AF patients at
ow clinical risk (clinical risk score of 5) had a high-risk
SS, compared with 12.3% of AF patients at high clinical
isk (clinical risk score of 5; p  0.83) (Fig. 2A). For
on-AF patients, the prevalence of high-risk perfusion
cans (SSS 9) increased from 11.7% of patients at low
linical risk to 21.6% of patients at high clinical risk (Fig.
B); however, this difference was not significant (p  0.13).
utcome. The SSS was a significant predictor of mortality
n both AF patients (p  0.001) (Fig. 3A) and non-AF
atients (p  0.001) (Fig. 3B). However, survival was
ignificantly worse in the AF patients (p  0.001) than in
he non-AF patients despite their similar SSS results
Fig. 4). The 5- and 10-year survival rates were 73% and
3%, respectively, in the AF patients compared with 82%
nd 60%, respectively, in the non-AF group (p  0.001).
sing a multivariate model, AF was independently associ-
ted with mortality (p  0.01) after adjusting for clinical
ariables and the results of SPECT imaging (Table 3). The
SS was also an independent predictor of mortality (p 
.04). The interaction term between AF and SSS was
ignificant (p  0.03) in this model, implying that the
elationship between SSS and mortality is different depend-
ng on the presence of AF (Fig. 5).
iscussion
here were no significant differences in abnormal SPECT
Figure 2 Percentage of High-Risk
SSS by Clinical Risk Groups
(A) Atrial fibrillation patients; (B) non-atrial
fibrillation patients. SSS  summed stress score.mages or SSS categories between asymptomatic patients
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September 11, 2007:1080–5 CAD Screening for Asymptomatic AFith and without AF. Thus, AF patients did not have an
xcess amount of occult CAD compared with patients
ithout AF. Despite the similarity in both overall SSS and
he prevalence of high-risk SSS between the AF and
on-AF groups, patients with AF had significantly higher
otal mortality rates. The increase in total mortality in
symptomatic patients with AF remained significant after
djusting for clinical variables and the stress myocardial
erfusion imaging results, suggesting that it was not due to
bstructive CAD.
CCF/ASNC appropriateness criteria. The American
ollege of Cardiology Foundation (ACCF)/American So-
iety of Nuclear Cardiology (ASNC) appropriateness crite-
ia include recommendations for CAD screening in asymp-
omatic patients with new-onset AF according to the
ramingham risk score (3). Intermediate-risk patients were
ot specifically addressed by these criteria. Low-risk pa-
ients were assigned to the uncertain category, indicating
hat the test may be appropriate but further research is
eeded in order to help further define this category (3).
creening for CAD in asymptomatic AF patients and a
igh-risk Framingham risk score was considered appropri-
te (3). In the present study we did not apply the Framing-
Figure 3 Kaplan-Meier Survival Curves According
to Summed Stress Score Risk Categories
Kaplan-Meier estimates for overall survival in atrial fibrillation (AF) patients (A) and
non-AF patients (B) according to summed stress score (SSS) risk categories. Survival
difference was statistically significant in both AF and non-AF patients (p  0.001 by log
rank statistic). Numbers below the graphs indicate numbers of patients available for
analysis at given time points.am scoring system, because this technique requires mea- Cured lipid values to calculate risk. Instead, we used a
ifferent clinical risk scoring system based only on clinical
ariables that has been validated in prior studies (6,7,9).
hen tested as a continuous variable, the clinical risk score
as associated with a higher SSS in the non-AF group but
ot in the AF group. Although the reasons for this are
ncertain, AF patients who underwent an exercise stress
PECT study had a reduced functional aerobic capacity
ompared with the control group. Thus, the potential for
nderestimating the extent and severity of ischemia exists.
owever, this only applies to approximately one-half of the
F patients; 48.4% underwent pharmacologic stress testing.
arlier studies. The only earlier study evaluating the out-
ome of AF patients undergoing stress SPECT was pub-
ished by Abidov et al. (2). Their study included higher-risk
F patients, with more than one-half being symptomatic
38% with angina and 16% with dyspnea) and/or having
nown CAD (23% with prior MI, 17% with prior coronary
Figure 4 Kaplan-Meier Survival Curves
Kaplan-Meier estimates for overall survival in atrial fibrillation (AF) and non-AF patients.
Differences between survival curves were statistically significant (p  0.001 by log
rank statistic). Numbers below the graph indicate numbers of patients available for
analysis at given time points.
ultivariate Predictors of Total Mortality
Table 3 Multivariate Predictors of Total Mortality
Hazard
Ratio 95% CI p Value
Age 1.08 (1.06–1.10) 0.001
Gender 1.06 (0.74–1.54) 0.74
Smoking 1.38 (1.13–1.69) 0.002
Family history 0.91 (0.64–1.29) 0.60
Hyperlipidemia 0.64 (0.48–0.85) 0.002
Diabetes 1.39 (1.14–1.68) 0.001
Hypertension 1.60 (1.18–2.16) 0.002
Antiarrhythmics 0.83 (0.44–1.59) 0.58
Beta-blockers 0.77 (0.56–1.05) 0.10
Calcium-channel blockers 1.08 (0.81–1.44) 0.59
Digoxin 0.93 (0.68–1.29) 0.68
Summed stress score 1.04 (1.00–1.07) 0.04
Summed rest score 1.02 (0.97–1.07) 0.46
Cardiac enlargement 1.20 (0.86–1.68) 0.28
Atrial fibrillation 1.51 (1.10–2.07) 0.01I  confidence interval.
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CAD Screening for Asymptomatic AF September 11, 2007:1080–5rtery bypass grafting, and 11% with prior percutaneous
oronary intervention). The principal finding in their study
ncluded a significant increase in both noncardiac and
ardiac death in patients with AF. Patients were classified
nto subsets on the basis of SPECT results (normal, mildly
bnormal, and moderately to severely abnormal). In all
ubsets, patients with AF had higher rates of cardiac death
han those without AF. In the present study also, overall
ortality was higher in AF patients, and this difference
ersisted after adjustment for the SSS. In both studies,
esting images were worse in AF versus non-AF patients;
owever, the SRS of AF patients in our study was less than
alf that reported by Abidov et al. (2). Owing primarily to
higher SRS, the mean SSS of AF patients reported by
bidov et al. (2) was significantly higher than that of
atients without AF; in contrast, the mean SSS between AF
nd non-AF patients in the present study was not signifi-
antly different. These differences in the SRS and SSS
etween the 2 studies likely reflect the underlying differ-
nces in each patient population as we excluded AF patients
ho were symptomatic or had known CAD.
ost-effective screening. Identifying patients who may
enefit from CAD screening in a cost-effective manner is
hallenging. In an earlier study, we found that 18% of
symptomatic diabetic patients without known CAD un-
ergoing screening stress SPECT had a high-risk scan (5).
ore than 25% of certain subgroups (patients with an
bnormal resting electrocardiogram and those with periph-
ral arterial disease) had a high-risk SSS. An accompanying
ditorial (10) suggested that the 25% prevalence of a
Figure 5 Relationship of Summed Stress Score
and Mortality in the Presence of Atrial Fibrillation
Kaplan-Meier estimates for overall survival in atrial fibrillation (AF) and non-AF
patients according to low-/intermediate-risk summed stress score (SSS) and high-
risk SSS. Differences between the survival curves of the low-/intermediate-risk
SSS AF and non-AF groups as well as between the high-risk SSS AF and non-AF
groups were statistically significant (p  0.001 by log rank statistic for the curves
as shown). Numbers below the graph indicate numbers of patients available for
analysis at given time points.igh-risk SSS in these subgroups was an excellent yield buthat the lower yield of screening all asymptomatic diabetic
atients needed to be augmented to be clinically- and
ost-effective. Only 14.4% of patients in the present study
ad a high-risk SSS, well below the recommended 25%
hreshold. Application of the clinical risk score did not
ncrease the yield of high-risk SSS results in AF patients.
tudy limitations. The study population reflects patients
eferred to a single tertiary center. Our results may not be
pplicable to a broader community-based population. The
etermination of whether a patient had AF depended on its
resence at the time of the stress study; patients with
aroxysmal AF who were in sinus rhythm at the time of the
tress study were not included. Conversely, the possibility
xists that some patients in the control group had paroxys-
al AF that was unknown. Baseline clinical characteristics
ere similar between the 2 groups; however, the percentage
f patients with hypertension was modestly higher in the AF
roup, whereas a history of cigarette smoking and hyperlipid-
mia were more common in the non-AF group. The ACCF/
SNC appropriateness criteria used the Framingham risk
core to categorize AF patients as high risk or low risk for
AD; we used a different clinical risk scoring system, because
oncurrent cholesterol measurements were not available in all
atients or were confounded by the use of statins during the
tudy period. Total mortality was the only outcome variable
easured; thus, the type of death or the impact of cerebrovas-
ular accidents, MIs, or major bleeds on the observed increased
ortality rates in AF patients could not be studied.
onclusions
he findings of the present study indicate that routine
creening for CAD using stress SPECT in asymptomatic
F patients is no different than in age- and gender-matched
atients without AF, and that the low yield does not support
outine screening. The increased total mortality in AF
atients does not appear to be due to obstructive CAD.
hether certain subgroups (i.e., patients being considered
or type IC antiarrhythmic medications) would benefit more
rom stress SPECT is uncertain.
eprint requests and correspondence: Dr. J. Wells Askew, Mayo
linic, Gonda 5, 200 First Street SW, Rochester, Minnesota
5905. E-mail: askew.john@mayo.edu.
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